First Patient Dosed in IntelGenx’s Resumed ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease
20 Janeiro 2022 - 10:00AM
IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the
“Company”), a leader in pharmaceutical films, today announced that
patient dosing has resumed in the ongoing Phase 2a (“BUENA”)
clinical trial in patients with mild to moderate Alzheimer’s
Disease (“AD”) under a previously amended protocol using higher
doses of Montelukast VersaFilm®.
“Resumption of patient dosing after a
COVID-related interruption of the study of over one year is a
significant milestone for this novel drug repurposing program, and
we look forward to the BUENA trial producing valuable data that
will provide more complete insight into the safety, feasibility,
tolerability and efficacy of Montelukast VersaFilm® in patients
with mild to moderate AD,” commented Dr. Horst Zerbe, IntelGenx’s
CEO.
“A significant unmet medical need remains for
safe and effective treatments for mild to moderate AD,” said Dr.
Ludwig Aigner, a member of IntelGenx’s Scientific Advisory Board.
"We believe that Montelukast VersaFilm® has the potential to be
disease-modifying, and we are excited to have resumed patient
dosing in this proof of concept trial.”
About IntelGenx
IntelGenx is a leading drug delivery company
focused on the development and manufacturing of pharmaceutical
films.
IntelGenx’s superior film technologies,
including VersaFilm®, DisinteQ™, VetaFilm™ and transdermal
VevaDerm™, allow for next generation pharmaceutical products that
address unmet medical needs. IntelGenx’s innovative product
pipeline offers significant benefits to patients and physicians for
many therapeutic conditions.
IntelGenx's highly skilled team provides
comprehensive pharmaceuticals services to pharmaceutical partners,
including R&D, analytical method development, clinical
monitoring, IP and regulatory services. IntelGenx's
state-of-the-art manufacturing facility offers full service by
providing lab-scale to pilot- and commercial-scale production. For
more information, visit www.intelgenx.com.
Forward Looking Statements:
This document may contain forward-looking
information about IntelGenx's operating results and business
prospects that involve substantial risks and uncertainties.
Statements that are not purely historical are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and Section 27A of the Securities
Act of 1933, as amended. These statements include, but are not
limited to, statements about IntelGenx's plans, objectives,
expectations, strategies, intentions or other characterizations of
future events or circumstances and are generally identified by the
words "may," "expects," "anticipates," "intends," "plans,"
"believes," "seeks," "estimates," "could," "would," and similar
expressions. All forward looking statements are expressly qualified
in their entirety by this cautionary statement. Because these
forward-looking statements are subject to a number of risks and
uncertainties, IntelGenx's actual results could differ materially
from those expressed or implied by these forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, those discussed under
the heading "Risk Factors" in IntelGenx's annual report on Form
10-K, filed with the United States Securities and Exchange
Commission and available at www.sec.gov, and also filed with
Canadian securities regulatory authorities at www.sedar.com.
IntelGenx assumes no obligation to update any such forward-looking
statements.
Source: IntelGenx Technologies Corp.
For IntelGenx:
Stephen KilmerInvestor Relations (647)
872-4849stephen@kilmerlucas.com
Or
Andre Godin, CPA, CAPresident and CFOIntelGenx
Corp.(514) 331-7440 ext 203andre@intelgenx.com
Intelgenx Technologies (TSX:IGX)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Intelgenx Technologies (TSX:IGX)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024